/OSTX
OSTX Stock - OS Therapies Incorporated
Healthcare|BiotechnologyNYSE
$1.54-3.75%
$0.06 (-3.75%) • Dec 19
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.15
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.69
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OSTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.52 – $1.56
TARGET (TP)$1.77
STOP LOSS$1.42
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-4.04
52W High$7.00
52W Low$1.12
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-2,780 | $-4,220 | $-805 | $-1,159,642 | $-4,250 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-6,813,846 | $-4,342,647 | $-4,446,299 | $-4,837,355 | $-5,647 |
| Net Income | $-8,882,938 | $-7,791,584 | $-6,254,685 | $-7,420,248 | $-6,027 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.52 | $-0.39 | $-0.28 | $-0.33 | $-0.00 |
Company Overview
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$19
Average Target
↑ 1133.8% Upside
Now
$19
Low
$19
Average
$19
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 2nd 2025 | Lake Street | Initiation | Buy | $19 |
Earnings History & Surprises
OSTXBeat Rate
0%
Last 6 quarters
Avg Surprise
-42.4%
EPS vs Estimate
Beats / Misses
0/4
2 met exactly
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
No data
Q3 24
0.0%
$-0.26vs$-0.26
Q4 24
-125.0%
$-0.18vs$-0.08
Q1 25
0.0%
$-0.14vs$-0.14
Q1 25
-71.4%
$-0.24vs$-0.14
Q3 25
-26.7%
$-0.19vs$-0.15
Q4 25
-31.2%
$-0.21vs$-0.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.16 | $-0.21 | -31.2% | ✗ MISS |
Q3 2025 | Aug 19, 2025 | $-0.15 | $-0.19 | -26.7% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-0.14 | $-0.24 | -71.4% | ✗ MISS |
Q1 2025 | Mar 28, 2025 | $-0.14 | $-0.14 | 0.0% | = MET |
Q4 2024 | Nov 15, 2024 | $-0.08 | $-0.18 | -125.0% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.26 | $-0.26 | 0.0% | = MET |
Q2 2024 | May 20, 2024 | — | $-0.07 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.42 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.09 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Latest News
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
📈 PositiveBenzinga•Dec 15, 2025, 01:19 PM
OS Therapies Held An FDA Type C Meeting Regarding The Phase 2B Trial Of OST-HER2 To Prevent Or Delay Recurrent, Fully-resected, Pulmonary Metastatic Osteosarcoma, And Intends To File BLA By The End January 2026
📈 PositiveBenzinga•Dec 15, 2025, 11:13 AM
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
📈 PositiveBenzinga•Dec 9, 2025, 02:10 PM
OS Therapies Holds Pre-MAA With UK MHRA Regarding Phase 2b Human Clinical Trial Of OST-HER2 In Prevention Or Delay Of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
➖ NeutralBenzinga•Dec 9, 2025, 12:43 PM
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
📈 PositiveBenzinga•Dec 5, 2025, 07:00 PM
OS Therapies Says U.S. FDA Grants Waiver Of Application Fee For BLA Filing Of OST-HER2; Type C Meeting With FDA Scheduled On December 11
📈 PositiveBenzinga•Dec 5, 2025, 01:09 PM
OS Therapies Announces WHO's INN Expert Committee Approves Daznelimgene Lisbac For Non-Proprietary Name For Company's HER2
➖ NeutralBenzinga•Nov 25, 2025, 02:27 PM
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
📈 PositiveBenzinga•Nov 21, 2025, 01:12 PM
OS Therapies Intends To Spin Off OS Animal Health Into Standalone Public Entity
📈 PositiveBenzinga•Nov 20, 2025, 12:46 PM
Lake Street Maintains Buy on OS Therapies, Lowers Price Target to $17
➖ NeutralBenzinga•Nov 18, 2025, 06:08 PM
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
📈 PositiveBenzinga•Nov 17, 2025, 01:17 PM
OS Therapies Targets January 2026 BLA Filing for OST-HER2, Expects PRV Revenue in 2026
📈 PositiveBenzinga•Nov 17, 2025, 11:06 AM
OS Therapies Q3 EPS $(0.21) Misses $(0.13) Estimate
📉 NegativeBenzinga•Nov 17, 2025, 11:04 AM
OS Therapies Reports Additional Survival Data For OST-HER2 In Phase 2b Osteosarcoma Trial
📈 PositiveBenzinga•Oct 22, 2025, 01:20 PM
OS Therapies Granted Second Type C Meeting From U.S. Food & Drug Administration For Biologics Licensing Application Of OST-HER2 To Treat Pulmonary Metastatic Osteosarcoma
📈 PositiveBenzinga•Oct 17, 2025, 01:20 PM
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
📈 PositiveBenzinga•Oct 10, 2025, 12:35 PM
OS Therapies Reports 75% 2-Year Survival In OST-HER2 Phase 2b Osteosarcoma Trial Vs 40% Control; Regulatory Filings Planned 2025–26
📈 PositiveBenzinga•Oct 10, 2025, 10:05 AM
OS Therapies Announces Positive Regulatory Update Following October 6 Meeting With EMA Rapporteur, Dutch Medicines Evaluation Board
📈 PositiveBenzinga•Oct 9, 2025, 11:43 AM
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
📈 PositiveBenzinga•Sep 30, 2025, 12:55 PM
OS Therapies To Propose Immune Biomarker + OS Data As Surrogate Efficacy Endpoint For Accelerated Approval In FDA Type C Meeting
📈 PositiveBenzinga•Sep 30, 2025, 11:46 AM
Frequently Asked Questions about OSTX
What is OSTX's current stock price?
OS Therapies Incorporated (OSTX) is currently trading at $1.54 per share. The stock has moved -3.75% today.
What is the analyst price target for OSTX?
No analyst price targets are currently available for this stock.
What sector is OS Therapies Incorporated in?
OS Therapies Incorporated operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NYSE exchange.
What is OSTX's market cap?
OS Therapies Incorporated has a market capitalization of $0.05 billion, making it a small-cap company.
Does OSTX pay dividends?
No, OS Therapies Incorporated does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADAG
Adagene Inc.
$1.82
Mkt Cap: $0.1B
COEP
Coeptis Therapeutics, Inc.
$14.66
Mkt Cap: $0.1B
CRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
EQ
Equillium, Inc.
$1.15
Mkt Cap: $0.0B
HOWL
Werewolf Therapeutics, Inc.
$0.69
Mkt Cap: $0.0B
INKT
MiNK Therapeutics, Inc.
$11.59
Mkt Cap: $0.1B
IOBT
IO Biotech, Inc.
$0.66
Mkt Cap: $0.0B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
OTLK
Outlook Therapeutics, Inc.
$2.01
Mkt Cap: $0.1B
SPRB
Spruce Biosciences, Inc.
$78.74
Mkt Cap: $0.0B
Explore stocks similar to OSTX for comparison